Analyst Price Targets — BLCO
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 3, 2026 10:07 am | Yi Chen | H.C. Wainwright | $21.00 | $16.91 | TheFly | Bausch + Lomb price target raised to $21 from $20 at H.C. Wainwright |
| July 30, 2026 1:16 pm | — | UBS | $23.00 | $16.23 | TheFly | Bausch + Lomb price target raised to $23 from $21 at UBS |
| July 28, 2026 10:42 am | — | UBS | $21.00 | $16.28 | TheFly | Bausch + Lomb initiated with a Buy at UBS |
| July 6, 2026 12:40 pm | — | Evercore ISI | $17.00 | $17.06 | TheFly | Bausch + Lomb price target raised to $17 from $16 at Evercore ISI |
| April 30, 2026 1:05 pm | — | Deutsche Bank | $16.00 | $15.55 | TheFly | Bausch + Lomb price target lowered to $16 from $18 at Deutsche Bank |
| February 23, 2026 1:27 pm | — | H.C. Wainwright | $20.00 | $17.64 | TheFly | Bausch + Lomb price target raised to $20 from $17 at H.C. Wainwright |
| February 19, 2026 12:24 pm | — | Stifel Nicolaus | $16.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $16 from $15 at Stifel |
| February 19, 2026 12:23 pm | — | Deutsche Bank | $18.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $18 from $15 at Deutsche Bank |
| February 19, 2026 11:29 am | — | Barclays | $20.00 | $17.67 | TheFly | Bausch + Lomb price target raised to $20 from $17 at Barclays |
| February 17, 2026 1:04 pm | — | Stifel Nicolaus | $15.00 | $17.25 | TheFly | Bausch + Lomb price target raised to $15 from $14 at Stifel |
Latest News for BLCO
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the publication of new research on real world experience with enVista Aspire and enVista Aspire toric intraocular lenses (IOLs). The study, published in the journal Ophthalmology and Therapy, found that these enhanced monofocal…
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced findings from a new survey highlighting a significant awareness gap around dry eye and its association with perimenopause and menopause. The survey found that dry eye remains one of the least recognized symptoms experienced during…
BLCO advances two eye-health candidates after positive trial results, with combined estimated peak sales exceeding $2 billion.
Bausch + Lomb Corporation (BLCO) Discusses Results and Development Plans for Dual Action Dry Eye Medicine and Lead Ocular Surface Pain Candidate Transcript
Bausch + Lomb NYSE: BLCO said it plans to advance a dual-action dry eye treatment into Phase III development after a Phase II study showed statistically significant improvement in corneal staining at day 15, although the trial did not meet its primary endpoint at day 29.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BLCO.
U.S. House Trading
No House trades found for BLCO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.